Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ampio Pharmaceuticals Inc Announces Positive Results For Ampion In Osteoarthritis Of The Knee Clinical Trial

Wednesday, 14 Aug 2013 08:00am EDT 

Ampio Pharmaceuticals Inc announced positive results from the SPRING study ( NCT01839331) of Ampion for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically meaningful reduction in pain. 

Company Quote

0.03 +1.13%
30 Jul 2015